1-3 of 3
John P. Galvin, MD, MPH
Close
Sort by
Journal Articles

Exploring the Potential of JAK1/2 Inhibitor Ruxolitinib with Reduced Intensity Hematopoietic Cell Transplantation (HCT) for Myelofibrosis: Stage I Results of a Prospective Trial Conducted through the Myeloproliferative Disorders - Research Consortium (MPD-RC)

Vikas Gupta, MD, Heidi E. Kosiorek, MS, Rebecca B Klisovic, MD, John P. Galvin, MD MPH, Dmitriy Berenzon, MD, Abdulraheem Yacoub, MD, Ruben A. Mesa, MD, Gianni Tognoni, Giuseppe Prosperini, Alessandra Di Lelio, Eliseo Serone, Lorenzo Marfisi, Alicia Orellano, Lee Potiphar, Mohamed E Salama, MD, Rona Singer Weinberg, PhD, Amylou C. Dueck, PhD, Adam Mead, MD PhD, John O. Mascarenhas, MD MS, Ronald Hoffman, MD
Journal: Blood
Blood (2016) 128 (22): 1126.
https://doi.org/10.1182/blood.V128.22.1126.1126
Published: 2016
Journal Articles

An Institutional Experience: Correlation Between Absolute Lymphocyte Count and Survival Outcome After Reduced Intensity Conditioning Allogeneic Stem Cell Transplant in Patients with Hematologic Malignancies

Kehinde U.A. Adekola, MBBS, John P. Galvin, MD, MPH, Vaibhav Sahai, MD, MSc, Oluwatoyosi A. Onwuemene, MD, Joanne Monreal, John Cashy, PhD, Jayesh Mehta, MD
Journal: Blood
Blood (2012) 120 (21): 4541.
https://doi.org/10.1182/blood.V120.21.4541.4541
Published: 2012
Journal Articles

Long-Term Remission After Hematopoietic Stem Cell Transplantation for Refractory Cutaneous T Cell Lymphoma

John P. Galvin, MD, MPH, Joanne Monreal, Joan Guitart, MD, Steve T. Rosen, MD, Timothy Kuzel, MD, Jayesh Mehta, MD
Journal: Blood
Blood (2012) 120 (21): 2028.
https://doi.org/10.1182/blood.V120.21.2028.2028
Published: 2012